Similar Articles
281 Novel prognostic factors after radical resection of hepatocellular carcinoma: Updating an old issue
282 Predictive value of NLR, Fib4, and APRI in the occurrence of liver failure after hepatectomy in patients with hepatocellular carcinoma
283 Direct-acting antivirals failed to reduce the incidence of hepatocellular carcinoma occurrence in hepatitis C virus associated cirrhosis: A real-world study
284 Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease
285 Sorafenib plus transarterial chemoembolization vs sorafenib alone for patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis
286 Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma
287 What are the changes in the hotspots and frontiers of microRNAs in hepatocellular carcinoma over the past decade?
288 Identification of the key genes and mechanisms associated with transcatheter arterial chemoembolisation refractoriness in hepatocellular carcinoma
289 Comparative study between Embosphere® and Marine gel® as embolic agents for chemoembolization of hepatocellular carcinoma
290 C-reactive protein to albumin ratio predict responses to programmed cell death-1 inhibitors in hepatocellular carcinoma patients
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA